MIV Therapeutics Details Exceptional Performance on HAp Coatings for Coronary Stents at Leading Biomedical Conference; Company Outlines Encouraging New Research Data at Conference of Canadian Medical and Biological Engineering Society.

VANCOUVER, British Columbia -- MIV Therapeutics, Inc. (OTCBB:MIVT) (FWB:MIV), a leading developer of new generation biocompatible coatings and advanced drug delivery systems for cardiovascular stents and other implantable medical devices, announced today that it has presented recent research progress on hydroxyapatite (HAp) coatings for stents, which indicated the Company's proprietary coatings for coronary stents far outperformed technologies and products currently in use.

MIVT scientific personnel presented the recent data at the 29th Conference of the Canadian Medical and Biological Engineering Society, a leading gathering of biomedical researchers and industry leaders. The Conference was held June 1-3 in Vancouver, BC.

Dr. Tom Troczynski, Vice President of Coatings at MIVT and a Professor of Ceramics at the University of British Columbia delivered an oral presentation entitled, "Hydroxyapatite Coatings for Coronary Stents - Materials Processing and In-Vivo Evaluation Results". The paper was co-authored by A. Rajtar, M. Lien, D. Smith and M. Tsui of MIVT, and Dr. Q. Yang of UBC.

The presentation discussed the methods for deposition of dense ultra-thin HAp, and the process variations to achieve microporous thicker HAp films designated to carry drugs for slow release after stent implantation. The microporous films are designed to remain highly biocompatible even after all drug material is eluted from the coating.

Both types of coatings are under extensive evaluation (in-vitro and in-vivo) in short-term (1 month) trials and medium term 6 month trials, in several laboratories in North America and Europe. The presentation detailed the trials' parameters and the very positive outcome of the short-term trials. The results of medium-term trials are due shortly.

The presentation concluded that HAp remains highly biocompatible independent of the presence or absence of drugs within the coating. In this respect, HAp performance far exceeds polymer-based coatings, wherein drugs are necessary to sustain acceptable coating performance.

"MIVT is eager to communicate the progress on its novel technologies for coating cardiovascular stents," said Dr. Troczynski. "We take on this task during major global cardiovascular events, as well as local conferences in Canada. This strengthens our links to the local scientific and clinical communities which can benefit from our results."

MIVT has entered the critical stage preceding commercialization of its technologies, according to Arc Rajtar, MIVT's Chief Technology Officer. "Our comprehensive testing and evaluation program continues to evaluate performance of our coating and drug delivery technologies in preparation for clinical trials scheduled to commence in the near future," Mr. Rajtar said. "We are methodically completing steps necessary to enter this decisive phase leading towards successful commercialization of our technologies."

About the Canadian Medical and Biological Engineering Society

The CMBES is Canada's principal society for engineering in medicine and biology. It is affiliated with the International Federation for Medical and Biological Engineering (IFMBE). The Society's aims are twofold:

--scientific and educational: directed toward the advancement of the theory and practice of medical device technology; and

--professional: directed toward the advancement of all individuals in Canada who are engaged in interdisciplinary work involving engineering, the life sciences and medicine

The CMBES organizes national medical and biological engineering conferences in various cities across Canada. In addition, the CMBES conference sponsors seminars, which include peer-reviews, technical paper presentations, exhibits of current medical devices, a continuing education program, workshops, symposia, and networking opportunities.

The Society website and further information on the Conference can be found at http://www.cmbes.ca/.

About MIV Therapeutics Inc.

MIV Therapeutics is developing a next-generation line of advanced biocompatible coatings for passive and drug-eluting applications on cardiovascular stents and a broad range of other implantable medical devices. The Company's ultra-thin coating formulation is designed to protect surrounding tissue from potentially harmful interactions with bare metallic stents. The Company's unique ultra-thin coating platform is derived from an organic material called hydroxyapatite (HAp) which has demonstrated excellent safety and biocompatibility in vivo animal studies. Hydroxyapatite is a bioactive porous material that makes up the bone mineral and matrix of teeth and is widely used today as a bone substitute material and for coatings on implantable fixation devices in orthopedic, dental and other applications. The Company's novel polymer-free drug eluting technologies based on Hydroxyapatite could also provide an attractive alternative to current polymer-based drug eluting coatings on the stent market, which have been associated with undesirable medical effects. The Company's drug eluting coatings are additionally designed to suit a broad range of implantable medical devices that could benefit from highly customizable drug release profiles. MIVT has a Collaborative Research Agreement (CRA) with the University of British Columbia and has received Government grant for its research program on the "Development of Novel Drug Eluting Composite Coatings for Cardiovascular Stents," under the National Research Council-Industrial Research Assistance Program (NRC-IRAP). Under this sponsorship, the Company is expected to complete its drug-eluting research and development program and to reach product commercialization stage. For more information, please visit http://www.trilogy-capital.com/tcp/mivt/website.html. To read or download MIV Therapeutics' Investor Fact Sheet, visit http://www.trilogy-capital.com/tcp/mivt/factsheet.html. To obtain daily and historical Company stock quote data, and recent Company news releases, visit http://www.trilogy-capital.com/tcp/html/mivt.htm. MIVT is traded on the Frankfurt, Germany, stock exchange under the symbol MIV.

Forward-Looking Statements

Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements. Such statements are indicated by words or phrases such as "believe," "will," "breakthrough," "significant," "indicated," "feel," "revolutionary," "should," "ideal," "extremely" and "excited." These statements are made under "Safe Harbor" provisions of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those described in forward-looking statements and are subject to risks and uncertainties. See the Company's filings with the Securities and Exchange Commission including, without limitation, the Company's recent Form 10-K and Form 10-Qs, which identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements.